JP2022513379A5 - - Google Patents
Info
- Publication number
- JP2022513379A5 JP2022513379A5 JP2021547607A JP2021547607A JP2022513379A5 JP 2022513379 A5 JP2022513379 A5 JP 2022513379A5 JP 2021547607 A JP2021547607 A JP 2021547607A JP 2021547607 A JP2021547607 A JP 2021547607A JP 2022513379 A5 JP2022513379 A5 JP 2022513379A5
- Authority
- JP
- Japan
- Prior art keywords
- msc
- polypeptide
- seq
- promoter
- aoah
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752000P | 2018-10-29 | 2018-10-29 | |
| US62/752,000 | 2018-10-29 | ||
| PCT/CA2019/051526 WO2020087160A1 (en) | 2018-10-29 | 2019-10-29 | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513379A JP2022513379A (ja) | 2022-02-07 |
| JP2022513379A5 true JP2022513379A5 (cg-RX-API-DMAC7.html) | 2022-08-05 |
| JP7372982B2 JP7372982B2 (ja) | 2023-11-01 |
Family
ID=70462996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547607A Active JP7372982B2 (ja) | 2018-10-29 | 2019-10-29 | Aoahを過剰発現する遺伝子組換え間葉系幹細胞及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220010281A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3874029B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7372982B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210086662A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166729A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019370629A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2962812T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282820A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202103509RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020087160A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302060A (en) * | 2020-10-16 | 2023-06-01 | Ottawa Hospital Res Inst | Cell-based therapy for viral diseases |
| CN116570711A (zh) * | 2022-12-21 | 2023-08-11 | 上海交通大学医学院附属第九人民医院 | 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用 |
| WO2026101889A2 (en) * | 2024-11-06 | 2026-05-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Acyloxyacyl hydrolase and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929604A (en) * | 1986-05-28 | 1990-05-29 | Board Of Regents, The University Of Texas System | Lipopolysaccharides of reduced toxicity and the production thereof |
| US5281520A (en) * | 1990-09-12 | 1994-01-25 | Zymogenetics, Inc. | Method for producing acyloxyacyl hydrolase |
| CN101378764A (zh) * | 2005-12-09 | 2009-03-04 | 贝勒研究院 | 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测 |
| JP2011528566A (ja) * | 2008-07-21 | 2011-11-24 | コンプジェン リミティッド | アンジオポエチン由来ペプチド |
| GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
| JP2012529895A (ja) * | 2009-06-19 | 2012-11-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗egfr抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法 |
| EP2626369A1 (en) * | 2011-11-24 | 2013-08-14 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Engineered mesenchymal stem cells and their therapeutic use |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| RU2658490C2 (ru) * | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| CA2928852A1 (en) * | 2013-11-01 | 2015-05-07 | Regeneron Pharmaceuticals, Inc. | Angiopoietin-based interventions for treating cerebral malaria |
| WO2015090229A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| KR102213527B1 (ko) * | 2014-06-30 | 2021-02-09 | 타이제닉스, 에스.에이.유. | 패혈증 치료용 중간엽 기질세포 |
| PL3242933T3 (pl) * | 2015-01-08 | 2019-08-30 | Apceth Gmbh & Co. Kg | Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat) |
| CA3172801A1 (en) * | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| CN108430480B (zh) * | 2015-09-15 | 2022-08-02 | 康干细胞生物科技有限公司 | 一种包含过表达sod3的干细胞作为活性成分的炎症性疾病的预防或治疗用组合物 |
-
2019
- 2019-10-29 EP EP19878837.4A patent/EP3874029B1/en active Active
- 2019-10-29 JP JP2021547607A patent/JP7372982B2/ja active Active
- 2019-10-29 KR KR1020217015632A patent/KR20210086662A/ko not_active Ceased
- 2019-10-29 AU AU2019370629A patent/AU2019370629A1/en not_active Abandoned
- 2019-10-29 CN CN201980071846.5A patent/CN113166729A/zh active Pending
- 2019-10-29 WO PCT/CA2019/051526 patent/WO2020087160A1/en not_active Ceased
- 2019-10-29 US US17/289,311 patent/US20220010281A1/en not_active Abandoned
- 2019-10-29 ES ES19878837T patent/ES2962812T3/es active Active
- 2019-10-29 SG SG11202103509RA patent/SG11202103509RA/en unknown
-
2021
- 2021-04-29 IL IL282820A patent/IL282820A/en unknown